Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
Формат:	Өгүүллэг
Хэл сонгох:	English
Хэвлэсэн:	Taylor & Francis Group 2019-06-01
Цуврал:	CNS Oncology
Нөхцлүүд:	bevacizumab glioblastoma glioma long term progression recurrence
Онлайн хандалт:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

Ижил төстэй зүйлс

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
-н: Alissa Thomas, зэрэг
Хэвлэсэн: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
-н: Josie Hayes, зэрэг
Хэвлэсэн: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
-н: Patrick Roth, зэрэг
Хэвлэсэн: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
-н: Bai X, зэрэг
Хэвлэсэн: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
-н: Soufyan Annakib, зэрэг
Хэвлэсэн: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
-н: Joan Manel Gasent Blesa, зэрэг
Хэвлэсэн: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
-н: D. R. Naskhletashvili, зэрэг
Хэвлэсэн: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
-н: Mesti Tanja, зэрэг
Хэвлэсэн: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
-н: Moire Cuncannon, зэрэг
Хэвлэсэн: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
-н: SiYao Wei, зэрэг
Хэвлэсэн: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
-н: Tomohiro Hosoya, зэрэг
Хэвлэсэн: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
-н: Mesti Tanja, зэрэг
Хэвлэсэн: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
-н: N. García-Romero, зэрэг
Хэвлэсэн: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
-н: Masahiro Nishikawa, зэрэг
Хэвлэсэн: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
-н: Zhaoyan Chen, зэрэг
Хэвлэсэн: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
-н: Kathleen Van Dyk, зэрэг
Хэвлэсэн: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
-н: Amy eBarone, зэрэг
Хэвлэсэн: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
-н: Hiroyuki Tatekawa, зэрэг
Хэвлэсэн: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
-н: Rebecca Kassubek, зэрэг
Хэвлэсэн: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
-н: Celina Bihan, зэрэг
Хэвлэсэн: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
-н: Eudocia Q. Lee, зэрэг
Хэвлэсэн: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
-н: Margarida Simão-Rafael, зэрэг
Хэвлэсэн: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
-н: Pia Banerjee, зэрэг
Хэвлэсэн: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
-н: Ramon F. Barajas, зэрэг
Хэвлэсэн: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
-н: George Ansstas, зэрэг
Хэвлэсэн: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
-н: Marina Petkovic, зэрэг
Хэвлэсэн: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
-н: Barbara Castelli, зэрэг
Хэвлэсэн: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
-н: Giovanni Luca Gravina, зэрэг
Хэвлэсэн: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
-н: Dong Liu, зэрэг
Хэвлэсэн: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
-н: Barbara Castelli, зэрэг
Хэвлэсэн: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
-н: Samy Ammari, зэрэг
Хэвлэсэн: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
-н: Oguz Ozel, зэрэг
Хэвлэсэн: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
-н: Emil Lou, зэрэг
Хэвлэсэн: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
-н: Seung Won Choi, зэрэг
Хэвлэсэн: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
-н: Minjie Fu, зэрэг
Хэвлэсэн: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
-н: José M. Duhart, зэрэг
Хэвлэсэн: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
-н: Valerie J. Marallano, зэрэг
Хэвлэсэн: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
-н: Jarosław Bała, зэрэг
Хэвлэсэн: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
-н: Lei She, зэрэг
Хэвлэсэн: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
-н: Shanmu Jin, зэрэг
Хэвлэсэн: (2024-03-01)